XBI State Street SPDR S&P Biotech ETF

Range, yield & payout streak

Based on Yahoo annual dividend totals through 2025 (excludes incomplete 2026).

BDC / cash pass-through vs ordinary dividend

ETF / fund — distributions depend on the underlying basket and fund policy. Yield is not a corporate “safety” rating.

Remember: high yield ≠ safer. Pass-through vehicles (BDC / REIT) can show high distributions by design while carrying credit, rate, or occupancy risk.

Dividend safety rating

High yield ≠ safer — elevated yield often prices higher risk or return-of-capital. Payout streak (non-decreasing annual totals): ~3 years.

Dividend history trend (recent payments)

Sourced from Yahoo via yfinance. Gaps or missing rows = data unavailable, not zeroes we invented.

Pass-through / BDC mechanics (deeper)

ETF / fund — distributions depend on the underlying basket and fund policy. Yield is not a corporate “safety” rating.

Advanced frame: for ordinary payers, focus on earnings/FCF coverage and balance-sheet flexibility. For REITs, focus on AFFO/FFO trends, occupancy, and debt ladders. For BDCs, focus on NII vs distribution, non-accruals, leverage vs statutory limits, and NAV drift. This page still is not a Crystal Signals entry card — no Counsel fire / manage stamp here.

Full company blurb

In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").